Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Grayscale's New Zcash ETF Has Gathered $1 Billion in Assets in Just 30 Days. Here's Why Investors Are So Bullish on Zcash.

The privacy coin has been a standout performer in a tough crypto market.

In just 30 days, Grayscale's new Zcash ETF has amassed a staggering $1 billion in assets, positioning it among the top 1% of ETFs launched in the past decade. This remarkable growth follows Zcash's impressive 149% surge in value over the same year, making it the leading privacy coin by market capitalization. The main driver behind Zcash's bullish outlook is the increasing demand for financial privacy.

Unlike most cryptocurrencies, Zcash offers users the choice between transparent and shielded addresses, with the latter utilizing a cryptographic method called zk-SNARKs to encrypt transaction details. This allows for the anonymization of transaction data, setting Zcash apart from competitors like Monero that lack transparent transactions.

Additionally, Zcash shares Bitcoin's inherent scarcity, with a hard cap of 21 million ZEC, and its issuance is reduced roughly every four years, potentially driving up prices if demand remains strong. However, the privacy aspect of Zcash has also raised regulatory concerns, as it has been associated with illicit activities like money laundering.

Despite these challenges, Zcash remains available on major exchanges, including Coinbase, although regulatory actions could impact its future trading landscape. The high expense of the Zcash ETF could deter some investors, as it charges a 2.5% management fee. Nonetheless, for those bullish on privacy coins and prepared to hold long-term, Zcash could serve as a valuable addition to a diversified portfolio.

Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Also reported by 1 other outlet

Read the original at fool.com →

More in Finance & Markets

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

Amgen trades at a lower valuation multiple, but Johnson & Johnson's fortress balance sheet and stronger free cash flow tell a different story about financial resilience.

  • Amgen reported $36.7B revenue in FY 2025, 10% growth, 21% net margin
  • Johnson & Johnson reported $94.2B revenue in FY 2025, 6% growth, 28.5% net margin
  • Johnson & Johnson has lower debt-to-equity ratio (0.6x) vs Amgen's 6.3x

More from Saturday 24 October →